- Home
- TRML vs WIW Comparison
TRML vs WIW Comparison
Compare TRML & WIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRML
- WIW
- Stock Information
- Founded
- TRML 2021
- WIW 2004
- Country
- TRML United States
- WIW United States
- Employees
- TRML N/A
- WIW N/A
- Industry
- TRML Biotechnology: Pharmaceutical Preparations
- WIW Finance Companies
- Sector
- TRML Health Care
- WIW Finance
- Exchange
- TRML Nasdaq
- WIW Nasdaq
- Market Cap
- TRML 509.8M
- WIW 537.8M
- IPO Year
- TRML N/A
- WIW N/A
- Fundamental
- Price
- TRML $13.84
- WIW $8.78
- Analyst Decision
- TRML Strong Buy
- WIW
- Analyst Count
- TRML 6
- WIW 0
- Target Price
- TRML $45.20
- WIW N/A
- AVG Volume (30 Days)
- TRML 360.6K
- WIW 229.9K
- Earning Date
- TRML 03-13-2025
- WIW 01-01-0001
- Dividend Yield
- TRML N/A
- WIW 11.14%
- EPS Growth
- TRML N/A
- WIW N/A
- EPS
- TRML N/A
- WIW N/A
- Revenue
- TRML N/A
- WIW N/A
- Revenue This Year
- TRML $363.93
- WIW N/A
- Revenue Next Year
- TRML N/A
- WIW N/A
- P/E Ratio
- TRML N/A
- WIW N/A
- Revenue Growth
- TRML N/A
- WIW N/A
- 52 Week Low
- TRML $11.87
- WIW $8.01
- 52 Week High
- TRML $29.79
- WIW $9.37
- Technical
- Relative Strength Index (RSI)
- TRML 37.41
- WIW 57.78
- Support Level
- TRML $16.39
- WIW $8.63
- Resistance Level
- TRML $17.36
- WIW $8.83
- Average True Range (ATR)
- TRML 1.03
- WIW 0.06
- MACD
- TRML -0.35
- WIW 0.00
- Stochastic Oscillator
- TRML 1.72
- WIW 75.00
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
About WIW Western Asset Inflation-Linked Opportunities & Income Fund
Western Asset Inflation-Linked Opportunities and Income Fund is a diversified, closed-end management investment company. Its primary investment objective of the group is to provide current income for its shareholders. The secondary investment objective is capital appreciation with current income.